Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
By J. Bolinder, Ö. Ljunggren, J. Kullberg, L. Johansson, J. Wilding, A. Langkilde, J. Sugg, S. Parikh. Journal of Clinical Endocrinology and Metabolism, 2012
798 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology, Surgery
View Paper: https://www.semanticscholar.org/paper/58354cf0ca82111c0a70aa5562b36ea11361bec3
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Molecular Biology
In Surgery
Citations in the corpus
- Pharmacological management of obesity: an endocrine Society clinical practice guideline. (2015, background): “Hence, prioritizing metformin, incretin-based medications, and SGLT-2s as therapeutic strategies can reduce exercise-related hypoglycemia and potentially increase the safety and efficacy of exercise in patients with diabetes, thus supporting this important weight-reduction strategy (67, 68).”
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes (2013, result): “The increased excretion of glucose and associated calorie loss appear to be mainly responsible for the reduction in body weight, as substantiated in a previous study [9], although the initial reduction in body weight can be attributed to fluid loss.”